TerrAscend (TSNDF) Non-Current Debt (2020 - 2026)
TerrAscend (TSNDF) posted quarterly Non-Current Debt of $204.9 million for Q1 2026, up 11.83% year-over-year from $183.3 million in Q1 2025, and up 0.53% quarter-over-quarter from $203.8 million in Q4 2025.
TerrAscend (TSNDF) Non-Current Debt (2020 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Non-Current Debt for 7 consecutive years, with $204.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 11.83% year-over-year to $204.9 million; the TTM figure through Mar 2026 stood at $204.9 million (up 11.83% YoY), while the FY2025 annual figure was $203.8 million, up 11.11% from the prior year.
- Non-Current Debt improved to $204.9 million in Q1 2026 per TSNDF's latest filing, from $203.8 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $211.9 million in Q3 2025 and bottomed at $58.4 million in Q1 2024.
- Historically, Non-Current Debt has averaged $172.1 million across 5 years, with a median of $183.3 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Debt plunged 70.44% — and 2025, when it soared 213.74%.
- TerrAscend's Non-Current Debt stood at $145.9 million in 2022, then slumped by 57.74% to $61.6 million in 2023, then soared by 197.67% to $183.5 million in 2024, then increased by 11.11% to $203.8 million in 2025, then grew by 0.53% to $204.9 million in 2026.
- Business Quant data shows TSNDF's Non-Current Debt at $204.9 million in Q1 2026, $203.8 million in Q4 2025, and $211.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn | 183.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 183.23 Mn |
| Mar 31, 2026 | 204.93 Mn |
| Dec 31, 2025 | 203.85 Mn |
| Sep 30, 2025 | 211.91 Mn |
| Jun 30, 2025 | 199.12 Mn |
| Mar 31, 2025 | 183.25 Mn |
| Dec 31, 2024 | 183.46 Mn |
| Sep 30, 2024 | 182.58 Mn |
| Jun 30, 2024 | 171.93 Mn |
| Mar 31, 2024 | 58.41 Mn |
| Dec 31, 2023 | 61.63 Mn |
| Sep 30, 2023 | 203.65 Mn |
| Jun 30, 2023 | 180.40 Mn |
| Mar 31, 2023 | 197.57 Mn |
| Dec 31, 2022 | 145.85 Mn |
| Sep 30, 2022 | 172.32 Mn |
| Jun 30, 2022 | 180.78 Mn |
| Mar 31, 2022 | 184.56 Mn |
| Dec 31, 2021 | 179.49 Mn |
| Dec 31, 2020 | 171.34 Mn |